Preparation "diaron" for treatment of acute gastrointestinal diseases of newborn calves

FIELD: veterinary.

SUBSTANCE: preparation of treatment of gastrointestinal diseases in newborn calves, includes zeolite, tetracycline, sodium acetate and flour of dried leather bergenia rhizome (Bergenia crassifolia), at the following ratio of components, wt %: Zeolite 44.5-48.5; Sodium acetate 44.5-48.5; Flour from dried rhizome of leather bergenia (Bergenia crassifolia) 4.2-8.2; Tetracycline 1.0-2.0. Preparation is fed in dose of 35 g per head 2 times per day until recovery.

EFFECT: therapeutic efficiency makes 100%.

1 tbl, 4 ex


The invention relates to veterinary medicine, namely to the means of treatment of acute gastro-intestinal diseases of newborn calves.

Acute gastrointestinal disease of the newborn calves (OJCBNT) is the most common form of pathology calves observed in almost all the farms involved in dairy cattle. In many farms in the period of mass calving cows, which are usually held in the winter-stall period, animals, OJCBNT nature of this epidemic, affecting all emerging calves. If you do not carry out effective preventive and therapeutic measures, the mortality among patients with calves up to 90-100%.

OJCBNT include a large number of diseases which are accompanied with signs of disorder of digestion, and can be both infectious and non-infectious origin. They treat intractable diseases, which is explained not only by their etiology, but also the complexity of the pathogenesis - when they develop the disease of the whole body, accompanied by dysfunction of almost all internal organs.

It should be noted that to fight OJCBNT offered a huge number of methods and means, especially means of treatment. In recent years, more and more features of expensive imported drugs, however, many farms are not in status is to purchase them due to the high cost.

No doubt that the treatment OJCBNT can be successful when using complex tools, and not a single "wonderful" component of the drug. Treatment success can be achieved by simultaneous application of antimicrobial agents against dehydration and intoxication, raising the tone, normalizing digestion, healing the mucous membrane of the intestines, etc. through a variety of means separately requires many therapeutic manipulation (injection and vipac) on each sick calf. Therefore, the veterinary profession is not physically in the state are to perform all of the procedures, especially when mass disease of calves, because what they unwittingly simplify the treatment regimen, reducing the amount of drugs or manipulations, thereby reducing its effectiveness.

The number of therapeutic manipulations are best reduced by the use of drugs in the form of the combined mixtures used by feeding.

The combined drugs are analogs of known startin, rehydralyte, EEPROM, tromelin, redear and others. However, when using these drugs is not always achieved consistently high therapeutic effect due to the insufficient range of their medicinal properties. In addition, a significant disadvantage is the high cost.

Most Blimber is Kim technical solution selected as a prototype of the present invention, always gastrulation, containing in its composition the same zeolite Chivyrkuyskogo field - RIVERTWIN (patent No. 2145502). Gastrulation was used in some farms of the Chita region.

However, the effectiveness of gastrulation low, because it does not have antibacterial, tonic and protivosvertyvayuschih funds.

The aim of the present invention is to improve the effectiveness of treatment OJCBNT with simultaneous reduction of its value.

This goal is achieved by the fact that the drug Diuron consists of the following components, wt.%: zeolite - 44,5-48,5, sodium acetate - 44,5-48,5, flour from dried rhizomes of bergenia tolstolistnogo Bergenia crassifolia - 4,2-8,2, tetracycline - 1,0-2,0.

All components of dirona powder that is easily mixed with each other, not scarce, not the road, each of them has healing properties. With the combined use of therapeutic properties of each component enhance the properties of other components.

Diuron does not require pre-cooking prior to use, i.e. it directly feeding sick calves in the form of mist with water, with which you can easily cope calf.

RIVERTWIN (TU 10 RSFSR 359-88) with a particle size of from 0.1 to 0.3 mm pre-dried in a drying Cabinet at 110°C for 8 hours.

Rhizomes is bergenia tolstolistnogo (Bergenia crassifolia) are harvested in the autumn in the pine forests of Transbaikalia, dried in the shade to a moisture content of not more than 14% and crushed using a crusher. Then turn into flour in special mills.

Acetic acid sodium and tetracycline gain through the system "Saavedra" and other selling veterinary organization.

Sifted through a sieve components in the desired proportions is placed in an enamel container and stirred with a wooden spade. Then the resulting mixture was stirred at electromedicine for 20 min to obtain a homogeneous powder. Dosage form in the form of a grey powder Packed in polyethylene bags at 0.5 kg

Scientific-production experiments to investigate the effectiveness of Varona was carried out according to the following scheme:

Example 1. Used a drug, "diaron" at a minimum ratio of ingredients, wt.%: zeolite - 48,5; sodium acetate - 46,3; flour from dried rhizomes of bergenia tolstolistnogo Bergenia crassifolia - 4,2, tetracycline is 1.0.

Test therapeutic effectiveness of dirona conducted under production conditions on a farm in the period of mass calving cows. The experiment was carried out on newborn calves with well-defined clinical signs of gastrointestinal disease. According to the principle of analogues were divided into two groups - experimental and control 10 goal each in the following order: first the sick body of the spacecraft was included in the experimental group, the second control, the third - experienced, fourth in control etc.

The experimental calves were treated with varanam dose of 30-35 g per head depending on the body weight of the calf. The preparation was given twice a day with an interval of about 12 hours, excluding colostrum: the first time fully, then slowly started to feed with boiled water.

Control calves were treated with gastrulation according to the instruction. Take into account the following parameters: the duration of the disease, the nature of its flow during the period of treatment, frequency of giving drugs, the outcome of the disease.

In the experimental group after the double feeding of dirona recovered 50% of calves, 30% after three times, 10% of five-and 10% - after eight (after 4 days). Therapeutic efficacy of Varona was 100%. And in the control group one calf fell, the rest recovered in time from 48 to 120 hours. Therapeutic efficacy gastrulation was 90%.

Example 2. Diuron used in the average ratio of ingredients, wt.%: zeolite - 46,15; acetic acid sodium 46,15; flour from dried rhizomes of bergenia tolstolistnogo Bergenia crassifolia - 6,16; tetracycline - 1,54.

The scheme of experiment was similar to that in the first experiment. The duration of the disease in calves of the experimental group ranged from 48 to 72 hours, the treatment efficiency is 100%and in the control calves, respectively 4-5 days and 90%.

Example 3. Di is Ron used to the maximum proportions of the main ingredients, wt.%: zeolite - 44,5; acetic acid sodium 45,3; flour from dried rhizomes of bergenia tolstolistnogo Bergenia crassifolia - 8,2; tetracycline - 2,0.

The experiment was carried out by the same method as in the previous experiments. The duration of the disease in calves of the experimental group ranged from 48 to 72 hours, the treatment efficiency is 100%and in the control calves, respectively 4-6 days and 90%.

Example 4. From calves suffering from acute gastro-intestinal disorders, according to the principle analogues formed 4 experimental and one control group. For the treatment of calves used Diuron, consisting of the following ingredients, wt.%: zeolite - 46,15; acetic acid sodium 46,15; flour from dried rhizomes of bergenia tolstolistnogo Bergenia crassifolia - 6,16; tetracycline - 1,54. All experimental calves were treated with varanam 2 times a day in the following doses: in the first group of 25 g per head, the second 30, the third 35 and the fourth - 40 g per head. The control group of calves was used gastrulation as directed by 0.3 per 1 kg of body weight. The results are presented in table 1.

Thus, the tests showed high efficiency of dirona in acute gastro-intestinal disease of newborn calves.

In all experiments, all calves were treated with varanam, recovered. Small differences in the results depended on the ratio of ingredients in the drug and dose. The disease has been cured in accordance with the s 2-4 days after giving the drug from 4 to 7 times. Treatment efficacy was 100% in all experiments.

Table 1
therapeutic efficacy of dirona depending on dose
IndexA group of calvesControl
The number of calves that goal.1012121515
Single dose of Varona, g25303540-
Single dose gastrulation, g----10,0
The duration of treatment, daysthe 3.82,42,03,2 5,5
The multiplicity of processing calves during the period of treatment time754612
Recovered a goal.1012121510
Palo goal----2
The treatment efficiency, %100,0100,0100,0100,086,7

Among the control calves were observed mortality, disease duration ranged from 4 to 5.5 days. All experimental calves were pereboleli in the form of light, and control in severe and moderate forms.

Drug for the treatment of gastrointestinal diseases of newborn calves, including zeolite, characterized in that it additionally contains tetracycline, sodium acetate and flour from dried rhizomes of bergenia tolstolistnogo Bergenia crassifolia in the following ratio, wt.%

Zeolite44,5 is 48.5
Acetic acid sodium44,5 is 48.5
Flour from dried rhizomes
bergenia tolstolistnogo Bergenia crassifolia4,2-8,2


Same patents:

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly gastroenterology and surgery, and covers prevention of dialysis peritonitis (DP). Therefor, prior to the peritoneal dialysis (PD), a bio-sample from the patient's intestines is analysed for dysbacteriosis by one of the standard methods. If dysbacteriosis is diagnosed, prior to the PD, dysbacteriosis is treated by elimination at the first stage of detected excess conditionally-pathogenic and pathogenic intestinal microflora with antibacterial preparations, taking into account sensitivity thereto of said microflora. The second stage involves compensation of deficiency and restoration of normal intestinal microflora. The restoration of intestinal microflora is followed with the PD.

EFFECT: method provides effective prevention of DP development, eliminating risk of DP development in multiple prolonged courses of the PD.

1 ex

FIELD: medicine.

SUBSTANCE: carboxylic acid compounds are presented by formula (I) where R1 represents (1) hydrogen atom, (2) C1-4alkyl; E represents -CO-; R2 represents (1) halogen atom, (2) C1-6 alkyl, (3) trihalogen methyl; R3 represents (1) halogen atom, (2) C1-6alkyl; R4 represents (1) hydrogen atom; R5 represents (1) C1-6alkyl; represents phenyl; G represents (1) C1-6alkylene; represents 9-12-merous bicyclic heterocycle containing heteroatoms, chosen of 1-4 nitrogen atoms, one or two oxygen atoms; m represents 0 or an integer 1 to 4, n represents 0 or an integer 1 to 4, and i represents 0 or an integer 1 to 11 where R2 can be identical or different provided m is equal to 2 or more, R3 can be identical or different provided n is equal to 2 or more, and R5 can be identical or different provided i is equal to 2 or more; both R12 and R13, independently represent (1) C1-4alkyl, (2) halogen atom, (3) hydroxyl or (4) hydrogen atom, or R12 and R13 together represent (1) oxo or (2) C2-5alkylene and where provided R12 and R13 simultaneously represent hydrogen atom, carboxylic acid compound presented by formula (I), represents a compound chosen from the group including the compounds (1) - (32), listed in cl.1 of the patent claim. Besides the invention concerns a pharmaceutical composition based in the compound of formula I and to application of the compound of formula I for making the pharmaceutical composition.

EFFECT: there are produced new carboxylic acid derivatives with antagonistic activity with respect to DP receptor.

14 cl, 74 ex

FIELD: medicine.

SUBSTANCE: invention concerns feeding of cats and dogs. A weight-reduction composition contains tyrosine in amount not exceeding approximately 0.4 wt %, particularly in amount approximately 0.08 to approximately 0.38 wt % and preferentially approximately 0.2 to approximately 0.36 wt % on solids. Method of animal's weight reduction implies that it is considered whether an animal requires weight reduction and feeding an animal with overweight with feed containing a composition with low content of tyrosine. Method of decreasing food consumption provides feeding of an animal with overweight with feed containing said composition. The feed additive, additional food or delicacy for weight reduction in dogs and the cats contain tyrosine in amount less than 0.4 wt % on solids.

EFFECT: invention allows reducing weight in domestic animals with overweight or obesity.

24 cl, 4 dwg, 5 tbl

FIELD: veterinary.

SUBSTANCE: medicine contains symbiotic system of strains of lactic acid bacteria Lactobacillus acidophilus D-75 and D-76 of medicine "Vitaflor", enrofloxacin and twin-80 with following ingredients ratio (% wt) symbiotic microorganisms of "Vitaflor" medicine - 10-20; enrofloxacin - 75-85; twin-80 - 1-2.

EFFECT: medicine reduces murrain of young birds and favours increase of day average additional weight on 10-15%.

4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine and application of proline-specific endoproteases for peptide and protein hydrolysis. Invention involves application of proline-specific endoprotease with pH optimum under 5.5 for production of diet additive or medicine for in vivo treatment of celiac disease or diseases related to presence of proline-rich peptides in food, or as diet additive or medicine for celiac disease prevention.

EFFECT: enhanced hydrolysis of forage proteins with high proline content.

13 cl, 12 ex,10 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to experimental pharmacology, and concerns correction of normal microflora composition in experiment. It is ensured by introduction to laboratory animals of 6-piperidinomethyl-2,3-dihydroquercetin- C21H23NO7.

EFFECT: method provides extended range of chemical agents that provide normalisation of colon microflora composition.

1 tbl, 1 ex

FIELD: veterinary.

SUBSTANCE: medication includes the following components, wt %: Sulfadimezinum 11.5-15; Trimethoprim 2.0-3.6; Colistin 2.0-3.5; glucose up to 100. Before application the medication is dissolved in warm water or colostrums at 35-37°C or fed with forage. The medication is applied daily twice in the dosage of 100 mg/kg of body weight for 3-5 days, or for 5-7 days under severe course of disease.

EFFECT: enhanced efficiency of colibacteriosis treatment for form animals.

12 tbl, 4 ex

FIELD: chemistry, biochemistry.

SUBSTANCE: invention relates to area of microbiology and biotechnology and can be applied in agriculture. Novel strain Megasphaera elsdenii is characterised by ability to utilise lactate with degree from 40% to 90% even in presence of sugars. Strain with said ability is obtained by method, which includes culturing of sample of paunch liquid. Novel strain Megasphaera elsdenii is applied in method of treatment and prevention of lactic acidosis of ruminants, in composition of veterinary preparation for treatment and prevention of said disease, in method of milk productivity increasing and in method of increasing ruminants fattening efficiency, in method of increasing growth rate and reduction of time of ruminants fattening, in method of reducing morbidity, induced by digestion disorders, and death rate among ruminants from lactic acidosis, as well as in method of increasing efficiency of conversion of ruminants diet based on concentrated forages when transferring ruminant to said diet.

EFFECT: obtaining ability to carry out wide-scale treatment and prevention of lactic acidosis.

17 cl, 3 dwg, 18 tbl

FIELD: medicine.

SUBSTANCE: invention relates medicine area, in particular, gastroenterology, and concerns treatment of GI tract dysbacteriosis. A set containing agents, possessing antagonist action on a GI tract pathogenic microflora and agents for restoration of a normal GI tract microflora (eubiotics and bacteritic preparations), and also independent GI tract electrostimulators are used for this purpose. The method of GI tract dysbacteriosis treatment combines a diet, the specified agents, and also electrostimulator insertion before and-or in the course of treatment.

EFFECT: optimum conditions for effect of eubiotics and bacteritic preparations at the expense of preliminary normalisation of GE tract motor and evacuation functions.

2 cl

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula (I), their optically active stereoisomers, as well as to pharmaceutically acceptable salts possessing properties of ORL1 and µ-opiate receptors. In general formula , R1 represents H, alkyl(1-6C), []m represents-(CH2)m-, in which m equals 0 or 1, R2 represents halogen, CF3, alkyl(1-6C), phenyl, cyano, cyanoalkyl(1-3C), hydroxy, (1-3C)alkoxy, OCF3, acyl(2-7C), trifluoroacetyl, (1-3C)alkylsulfonyl or trifluoromethylsulfonyl, and n represents integer number 0-4 on condition that when n equals 2, 3 or 4, R2 substituents can be similar or different, A represents saturated ring, []0 and []p represents -(CH2)o and -(CH2)p, and o and p independently correspond to 0, 1 or 2, R3, R4, R5 and R6 independently represent hydrogen, alkyl(1-3C), or (R4 and R6) together can form alkylene bridge, containing 1-3 carbon atoms on condition that when o equals 2, R3 represents hydrogen, and when p equals 2, R5 represents hydrogen, R7 represents H, halogen, alkyl(1-6C). Invention also relates to pharmaceutical composition, intermediate compounds for obtaining formula (1) compounds.

EFFECT: compounds can be used for preparing medication for treating disorders and diseases such as alimentary behaviour disturbances, arterial hypertension.

8 cl, 3 dwg, 1 tbl, 45 ex

FIELD: medicine; veterinary science.

SUBSTANCE: cerebrolysin dosed 1 ml once a day within 3-4 days is injected intramuscularly to an affected animal.

EFFECT: high effectiveness.

1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine and represents pharmacologic composition for diarrhea treatment in case of irritate bowels syndrome in women, which contains from 0.002 to 0.02 mg of ramosetron hydrochloride as daily dose or equivalent molar amount of ramosetron or its other pharmacologically acceptable salt as active ingredient.

EFFECT: invention ensures more efficient treatment of diarrhea syndrome in case of irritate bowels syndrome in women.

6 cl, 10 ex

FIELD: medicine; veterinary medicine.

SUBSTANCE: medical product contains polyvinylpyrolidone, Furacilinum, glucose, Acidum ascorbinicum and sodium hypochlorite at the certain component proportion.

EFFECT: reduction of diarrhea duration on 36% (to 2.8 days); calf safety at level of 95% and additional weight increase on 15-44% after treatment, reduction of medical products consumption.

2 tbl, 2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention concerns a combination for proliferative disease treatment which contains antidiarrheal agent and epothylon derivative of formula (1) or epothylon derivative, method of diarrhoeia management, associated with epothylon introduction of formula (1), pharmaceutical composition, trade packing and medical product, including antidiarrheal agent and epothylon derivative.

EFFECT: compositions have improved efficiency.

9 cl, 6 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to antagonists of adenosine A2B receptors and their using in treatment of mammals in different pathological states, such as digestive, immunological, neurological disorders and cardiovascular diseases caused both hyper-proliferation of cells and their apoptosis and similar disorders. Also, invention relates to methods for synthesis of these compounds and pharmaceutical composition containing thereof. The aim of the present invention is use of compounds of the general formulae (I) and (II) for preparing pharmaceutical composition possessing antagonistic activity with respect to adenosine A2B receptors wherein radical values are given in the invention description.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

41 cl, 12 sch, 35 ex

FIELD: medicine.

SUBSTANCE: means has 0.001-0.05 mg of Ramozetron Hydrochloride as daily dose or equivalent molar quantity of Ramozetron or its other pharmaceutically permissible salt as active ingredient.

EFFECT: enhanced effectiveness of treatment.

12 cl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to pharmaceutical compositions with anti-diarrheic effect. Pharmaceutical composition comprises the therapeutically effective amount of loperamide hydrochloride as an active component and special additives. Lactose, starch, aerosil, talk and stearate are used as special additives. Pharmaceutical composition is prepared in the form of solid gelatinous capsules. Loperamide capsules satisfy all requirement of the State Pharmacopoeia of XI Edition. Invention provides bioavailability of the pharmaceutical composition of loperamide capsules at the level 98.5%.

EFFECT: improved and valuable pharmaceutical properties of composition.

3 cl, 1 tbl, 3 ex

FIELD: veterinary science.

SUBSTANCE: the suggested preparation for treating diarrhea in farm animals youngsters contains bismuth salt in the form of bismuth-potassium ammonium citrate and, additionally, polyethylenoxide, moreover, preferably, it contains 1.5-2.5%-polyethylenoxide solution and 1.5-2.5%-bismuth-potassium ammonium citrate solution. The method for treating diarrhea deals with introducing the above-mentioned preparation once or twice daily for 1-2 d at the dosage of 1-75 ml/kg body weight. In young foxes it should be introduced at the dosage of 60-75 ml/kg body weight, in calves - at the dosage of 1-3 ml/kg body weight, in lambs - at the dosage of 2-3 ml/kg body weight. Application of the present complex preparation and therapeutic method enables to shorten terms of therapy by 1.5-2 times, decreases expenses for therapy by 3-5 times and provides decreased toxicological impact the preparation upon animal body.

EFFECT: higher efficiency of therapy.

6 cl, 3 ex, 2 tbl

The invention relates to pharmaceutical

The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen

FIELD: medicine.

SUBSTANCE: invention present an oral care composition against dental deposit which contains an orally acceptable carrier and amount of compound of structure (I) effective with respect to antibacterial activity wherein R1 and R2 are independently chosen from lower C1-4alkyl groups, and R3 and R4 independently represent alkenyl or alkyl group with 1 to 20 carbon atoms. The composition can be presented as a tooth-paste or tooth gel which contains at least one moisture-retaining substance, at least one abrasive compound and amount of the compound presented by structure of formula (I) effective with respect to antibacterial activity. The composition containing compound of formula (I), can be used for preparing a drug for inhibition of bacteria growth in the mouth of an animal.

EFFECT: application of said agent allows effectively inhibiting bacteria growth in the mouth.

31 cl